The CAESAR IBD Project: Developing Therapeutic Antibodies for Pets
Inflammatory bowel disease (IBD) in dogs is a common but poorly managed chronic condition causing immense emotional and financial distress to pet owners. Based on the positive results of antibodies to treat IBD in humans they have...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
AGL2013-48998-C2-1-R
ESTRATEGIAS DE PROTECCION FRENTE A LA PESTE PORCINA AFRICANA...
Cerrado
AGL2014-52395-C2-2-R
PLATAFORMAS PEPTIDICAS MULTIEPITOPICAS PARA APLICACIONES VAC...
224K€
Cerrado
AGL2011-30563-C03-01
DISEÑO Y CONSTRUCCION DE ANTIGENOS QUIMERICOS POLIEPITOPICOS...
151K€
Cerrado
BES-2011-047361
DESARROLLO DE UNA VACUNA FRENTE A LA LEISHMANIOSIS CANINA. N...
43K€
Cerrado
AGL2008-00110
DESARROLLO DE VACUNAS RECOMBINANTES CON LAS PROTEINAS DE UNI...
117K€
Cerrado
AGL2017-84097-C2-1-R
DESARROLLO Y OPTIMIZACION DE NUEVAS VACUNAS Y ESTRATEGIAS AN...
145K€
Cerrado
Información proyecto CAESAR IBD Project
Duración del proyecto: 19 meses
Fecha Inicio: 2022-09-14
Fecha Fin: 2024-04-30
Líder del proyecto
ADIVO GMBH
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
3M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Inflammatory bowel disease (IBD) in dogs is a common but poorly managed chronic condition causing immense emotional and financial distress to pet owners. Based on the positive results of antibodies to treat IBD in humans they have been proposed for dogs. However, instead of investigating a new drug specific for them some antibodies developed for other purposes and species has been adapted (petization), which can trigger immune responses in pets, yielding ineffective therapies and causing further health complications. At Adivo we have developed and validated CAESAR platform, which is the first fully canine phage-display library to generate therapeutic antibodies specific for dogs overcoming the limitations of current petization techniques. Now we aim to use this technology to develop and validate an effective drug to treat IBD in dogs. This project will bring a cumulative profit of €41 M in the first five years of commercialization, an ROI of 14 and to hire over 15 professionals.